SEQUENCE LISTING

The patent application contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20190248897A1). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

1. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc, the Fc variant comprising a L234A amino acid substitution, a L235A amino acid substitution, and a D265S amino acid substitution, wherein the amino acid positions are numbered according to the EU index of Kabat.

2. The polypeptide of claim **1**, wherein the polypeptide further comprises at least one antigen-binding domain.

3. The polypeptide of claim **2**, wherein the antigen-binding domain comprises an scFv.

4. The polypeptide of claim **2**, wherein the antigen-binding domain comprises a Fab.

5. The polypeptide of claim **1**, wherein the polypeptide further comprises an scFv and a Fab.

6. The polypeptide of claim **1**, wherein the Fc variant further comprises amino acid substitutions T350V, L351Y, F405A, and Y407V, wherein the amino acid positions are numbered according to the EU index of Kabat.

7. The polypeptide of claim **1**, wherein the Fc variant further comprises amino acid substitutions T350V, T366L, K392L, and T394W, wherein the amino acid positions are numbered according to the EU index of Kabat.

8. The polypeptide of claim **1**, wherein the IgG is an IgG1.

9. The polypeptide of claim **1**, wherein the polypeptide comprises an antibody or an Fc fusion.

10. An antibody comprising the polypeptide of claim **1**.

11. The antibody of claim **10**, wherein the antibody is a monoclonal antibody, a humanized antibody, or a human antibody.

12. The antibody of claim **10**, wherein the antibody is multispecific.

13. The antibody of claim **10**, wherein the antibody is bispecific.

14. A dimer comprising the polypeptide of claim **1**.

15. A heterodimer comprising the polypeptide of claim **1**.

16. A pharmaceutical composition comprising the polypeptide of claim **1** and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising the antibody of claim **10** and a pharmaceutically acceptable carrier.

18. An isolated nucleotide sequence encoding the polypeptide of claim **1**.

19. A vector comprising the nucleotide sequence of claim **18**.

20. A host cell comprising the vector of claim **19**.

21. A method of producing a polypeptide, comprising culturing the host cell of claim **20**, and producing the polypeptide.

22. An isolated multispecific heteromultimer construct comprising:

a first polypeptide construct comprising a CD3 binding polypeptide construct that binds to a human CD3 complex on at least one CD3 expressing cell, wherein the first polypeptide construct is an scFv;

a second polypeptide construct comprising an antigen binding polypeptide construct that binds to a human CD19 target antigen on at least one B cell, wherein the second polypeptide construct is a Fab or an scFv; and

a heterodimeric human IgG1 Fc comprising a variant immunoglobulin CH3 domain comprising a first CH3 sequence and a second CH3 sequence, the first CH3 sequence comprising amino acid substitutions at L351, F405, and Y407, and the second CH3 sequence comprising amino acid substitutions at T366, K392, and T394, wherein the amino acid substitutions at L351 is L for Y, F, or W, at F405 is F for A or G, and at Y407 is Y for V, M, L, or I, and the amino acid substitutions at T366 is T for L, I, M, or V, at K392 is K for M, I, L, or V, and at T394 is T for W, Y, or F, and wherein each of the first polypeptide construct and the second polypeptide construct is linked to the N terminus of the heterodimeric human IgG1 Fc, wherein the numbering of the amino acid residues is according to the EU index as set forth in Kabat.

* * * * *